These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1709696)

  • 1. Chimeric polioviruses that include sequences derived from two independent antigenic sites of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies against FMDV in guinea pigs.
    Kitson JD; Burke KL; Pullen LA; Belsham GJ; Almond JW
    J Virol; 1991 Jun; 65(6):3068-75. PubMed ID: 1709696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV.
    Rieder E; Baxt B; Lubroth J; Mason PW
    J Virol; 1994 Nov; 68(11):7092-8. PubMed ID: 7523697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse.
    Barnett PV; Samuel AR; Pullen L; Ansell D; Butcher RN; Parkhouse RM
    J Gen Virol; 1998 Jul; 79 ( Pt 7)():1687-97. PubMed ID: 9680132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies.
    Stave JW; Card JL; Morgan DO
    J Gen Virol; 1986 Oct; 67 ( Pt 10)():2083-92. PubMed ID: 2428926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection conferred by TrpE fusion proteins containing portions of the C-terminal region of capsid protein VP1 of foot-and-mouth disease virus.
    Giavedoni LD; Kaplan G; Marcovecchio F; Piccone ME; Palma EL
    J Gen Virol; 1991 Apr; 72 ( Pt 4)():967-71. PubMed ID: 1849980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants.
    Stave JW; Card JL; Morgan DO; Vakharia VN
    Virology; 1988 Jan; 162(1):21-9. PubMed ID: 2827379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neutralization of foot-and-mouth disease virus O1 Campos by antibodies induced by a synthetic peptide].
    Piccone M; Zuloaga G; Marcovecchio F; Arese A; Monesiglio JC; Palma EL
    Rev Argent Microbiol; 1988; 20(2):69-75. PubMed ID: 2845477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct repertoire of antigenic variants of foot-and-mouth disease virus in the presence or absence of immune selection.
    Borrego B; Novella IS; Giralt E; Andreu D; Domingo E
    J Virol; 1993 Oct; 67(10):6071-9. PubMed ID: 7690417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of substituted and tandem-repeated peptides to probe the relevance of the highly conserved RGD tripeptide in the immune response against foot-and-mouth disease virus.
    Novella IS; Borrego B; Mateu MG; Domingo E; Giralt E; Andreu D
    FEBS Lett; 1993 Sep; 330(3):253-9. PubMed ID: 7690714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel antibody binding determinants on the capsid surface of serotype O foot-and-mouth disease virus.
    Asfor AS; Upadhyaya S; Knowles NJ; King DP; Paton DJ; Mahapatra M
    J Gen Virol; 2014 May; 95(Pt 5):1104-1116. PubMed ID: 24584474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif.
    Brown F; Benkirane N; Limal D; Halimi H; Newman JF; Van Regenmortel MH; Briand JP; Muller S
    Vaccine; 1999 Aug; 18(1-2):50-6. PubMed ID: 10501234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of an aphthovirus chimera of the glycoprotein of vesicular stomatitis virus.
    Grigera PR; Garcia-Briones M; Periolo O; la Torre JL; Wagner RR
    J Virol; 1996 Dec; 70(12):8492-501. PubMed ID: 8970972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenic properties and population stability of a foot-and-mouth disease virus with an altered Arg-Gly-Asp receptor-recognition motif.
    Ruiz-Jarabo CM; Sevilla N; Dávila M; Gómez-Mariano G; Baranowski E; Domingo E
    J Gen Virol; 1999 Aug; 80 ( Pt 8)():1899-1909. PubMed ID: 10466785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic comparison of different foot-and-mouth disease virus types using monoclonal antibodies defining multiple neutralizing epitopes on FMDV A5 subtypes.
    Saiz JC; Gonzalez MJ; Morgan DO; Card JL; Sobrino F; Moore DM
    Virus Res; 1989 May; 13(1):45-60. PubMed ID: 2473578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C.
    Mateu MG; Martínez MA; Capucci L; Andreu D; Giralt E; Sobrino F; Brocchi E; Domingo E
    J Gen Virol; 1990 Mar; 71 ( Pt 3)():629-37. PubMed ID: 1690261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and antigenicity of chimeric picornaviruses which express hepatitis A virus (HAV) peptide sequences: evidence for a neutralization domain near the amino terminus of VP1 of HAV.
    Lemon SM; Barclay W; Ferguson M; Murphy P; Jing L; Burke K; Wood D; Katrak K; Sangar D; Minor PD
    Virology; 1992 May; 188(1):285-95. PubMed ID: 1314456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic structure of chimeras of type 1 and type 3 poliovirus involving antigenic site 1.
    Minor PD; Ferguson M; Katrak K; Wood D; John A; Howlett J; Dunn G; Burke K; Almond JW
    J Gen Virol; 1990 Nov; 71 ( Pt 11)():2543-51. PubMed ID: 1701474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenic structure of chimeras of type 1 and type 3 polioviruses involving antigenic sites 2, 3 and 4.
    Minor PD; Ferguson M; Katrak K; Wood D; John A; Howlett J; Dunn G; Burke K; Almond JW
    J Gen Virol; 1991 Oct; 72 ( Pt 10)():2475-81. PubMed ID: 1717641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of neutralizing epitopes on foot-and-mouth disease virus.
    Pfaff E; Thiel HJ; Beck E; Strohmaier K; Schaller H
    J Virol; 1988 Jun; 62(6):2033-40. PubMed ID: 2835507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic sites of foot-and-mouth disease virus (FMDV): an analysis of the specificities of anti-FMDV antibodies after vaccination of naturally susceptible host species.
    Aggarwal N; Barnett PV
    J Gen Virol; 2002 Apr; 83(Pt 4):775-782. PubMed ID: 11907326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.